|
1
|
Fletcher CDM, Unni KK and Mertens F:
Pathology and genetics of tumours of soft tissue and bone. Lyon:
IARC. 2002.
|
|
2
|
Balke M, Ahrens H, Streitbuerger A,
Koehler G, Windelmann W, Gosheger G and Hardes J: Treatment options
for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol.
135:149–158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Durr HR, Maier M, Jansson V, Baur A and
Refior HJ: Phenol as an adjuvant for local control in the treatment
of giant cell tumor of the bone. Eur J Surg Oncol. 25:610–618.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Malawer MM, Bickels J, Meller I, Buch RG,
Henshaw RM and Kollender Y: Cryosurgery in the treatment of giant
cell tumor. A long term follow-up study. Clin Orthop Relat Res.
176–188. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marcove RC, Steth DS, Brien EW, Huvos AG
and Healey JH: Conservative surgery for giant cell tumors of the
sacrum. The role of cryosurgery as a supplement to curettage and
partial excision. Cancer. 74:1253–1260. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shi W, Indelicato DJ, Reith J, Smith KB,
Morris CG, Scarborough MT, Gibbs CP Jr, Mendenhall WM and Zlotecki
RA: Radiotherapy in the management of giant cell tumor of bone. Am
J Clin Oncol. 36:505–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin PP, Guzel VB, Moura MF, Wallace S,
Benjamin RS, Weber KL, Morello FA Jr, Gokaslan ZL and Yasko AW:
Long-term follow-up of patients with giant cell tumor of the sacrum
treated with selective arterial embolization. Cancer. 95:1317–1325.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lackman RD, Khoury LD, Esmail A and
Donthineni-Rao R: The treatment of sacral giant-cell tumours by
serial arterial embolisation. J Bone Joint Surg Br. 84:873–877.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Onishi H, Kaya M, Wada T, Sagoya S, Sasaki
M and Yamashita T: Giant cell tumor of the sacrum treatment with
selective arterial embolization. Int J Clin Oncol. 15:416–419.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Balke M, Campanacci L, Gebert C, Picci P,
Gibbons M, Taylor R, Hogendoorm P, Kroep J, Wass J and Athanasou N:
Bisphosphonate treatment of aggressive primary, recurrent and
metastatic giant cell tumour of bone. BMC Cancer. 10:4622010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishisho T, Hanaoka N, Endo K, Takahashi M
and Yasui N: Locally administered zoledronic acid therapy for giant
cell tumor of bone. Orthopedics. 34:e312–e315. 2011.PubMed/NCBI
|
|
12
|
Tse LF, Wong KC, Kumta SM, Huang L, Chow
TC and Griffith JF: Bisphosphonates reduce local recurrence in
extremity giant cell tumor of bone: A case-control study. Bone.
42:68–73. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chawla S, Henshw R, Seeger L, Choy E, Blay
JY, Ferrari S, Krope J, Grimer R, Reichardt P, Rutkowski P, et al:
Safety and efficacy of denosumab for adults and skeletally mature
adolescents with giant cell tumour of bone: Interim analysis of an
open-label, parallel-group, phase 2 study. Lancet Oncol.
14:901–908. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Raslin KA, Schwab JH, Mankin HJ,
Springfield DS and Hornicek FJ: Giant cell tumor of bone. J Am Acad
Orthop Surg. 21:118–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruggieri P, Mavrogenis AF, Ussia G,
Angelini A, Papagelopoulos PJ and Mercuri M: Recurrence after and
complications associated with adjuvant treatments for sacral giant
cell tumor. Clin Orthop Relat Res. 468:2954–2961. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ueda T, Morioka H, Nishida Y, Kakunaga S,
Tsuchiya H, Matsumoto Y, Asami Y, Inoue T and Yoneda T: Objective
tumor response to denosumab in patients with giant cell tumor of
bone: A multicenter phase II trial. Ann Oncol. 26:2149–2154. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rutkowski P, Ferrari S, Grimer RJ, Stalley
PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A,
et al: Surgical downstaging in an open-label phase II trial of
denosumab in patients with giant cell tumor of bone. Ann Surg
Oncol. 22:2860–2868. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shinozaki T, Saito K, Kobayashi T,
Yanagawa T and Takagishi K: Tartrate-resistant acid phosphatase 5b
is a useful serum marker for diagnosis and recurrence detection of
giant cell tumor of bone. Open Orthop J. 6:392–399. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Branstetter DG, Nelson SD, Manivel JC,
Blay JY, Chawla S, Thomas DM, Jun S and Jacobs I: Denosumab induces
tumor reduction and bone formation in patients with giant-cell
tumor of bone. Clin Cancer Res. 18:4415–4424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lau CP, Huang L, Wong KC and Kumta SM:
Comparison of the anti-tumor effect of denosumab and zoledronic
acid on the neoplastic stromal cells of giant cell tumor of bone.
Connect Tissue Res. 54:439–449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baron R, Ferrari S and Russell RG:
Denosumab and bisphosphonates: Different mechanisms of action and
effects. Bone. 48:677–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zebaze RM, Libanati C, Austin M,
Ghasem-Zadeh A, Hanley DA, Zanchetta JR, Thomas T, Boutroy S,
Bogado CE, Bilezikian JP and Seeman E: Differing effects of
denosumab and alendronate on cortical and trabecular bone. Bone.
59:173–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
